Register Login

INCANNEX HEALTHCARE INC. (IXHL)

(10% Negative) INCANNEX HEALTHCARE INC. (IXHL) Announces Delay in opportunity Development Timeline Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot March 12, 2026, 12:03 p.m.

    📋 INCANNEX HEALTHCARE INC. (IXHL) - Clinical Trial Update

    Filing Date: 2026-03-12

    Accepted: 2026-03-12 08:01:09

    Event Type: Clinical Trial Update

    Event Details:

    INCANNEX HEALTHCARE INC. (IXHL) Announces Clinical Trial Update INCANNEX HEALTHCARE INC. (IXHL) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: opportunity, statements
    • Clinical Stage: clinical trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: FDA
      • Targeting RA Inflammation and Pain Chronic inflammatory disorder affecting joints, but also other tissue types Immune system mistakenly attacking its own tissues Flare - ups and remission periods occur, making the condition challenging to treat NASDAQ:IXHL Hydroxychloroquine Cannabidiol Well - established Disease - Modifying Anti - Rheumatic Drug (DMARD). Evidence suggests it regulates immune system hyperactivity by interfering with antigen presentation by immune cells and decreasing TLR signaling . Downregulates pro - inflammatory cytokines, inhibiting production of key inflammatory mediators. Modulates non - cannabinoid receptor pathways, exerting analgesic effect and immune - driven inflammation. 32 IHL - 675A: A Proprietary Oral Anti - Inflammatory Therapeutic Designed to Treat Inflammation and Pain Associated with Rheumatoid Arthritis Oral fixed - dose combination of synthetic cannabidiol and hydroxychloroquine sulfate in Phase 2 for RA • IHL - 675A demonstrated to be well - tolerated and bioavailable in Phase 1 study IHL - 675A TRPV1 GPR55 NMDAR µ/ δ opioid receptor α 1 - adrenoceptor T - type Ca 2+ channel COX2 5 - HT 1A Inflammation 5 - HT 2A Inflammation Cannabidol Hydroxychloroquine NASDAQ:IXHL Late - stage pipeline of oral fixed - dose treatments and therapeutic regimens for large market chronic conditions NASDAQ:IXHL 33 INVESTMENT SUMMARY ~$70M capital position (as of December, 2025

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: INCANNEX HEALTHCARE INC.
    • Ticker Symbol: IXHL

Search

News categories